Results 11 to 20 of about 376,342 (317)

Biopsy confirmation of metastatic sites in breast cancer patients:clinical impact and future perspectives [PDF]

, 2014
Determination of hormone receptor (estrogen receptor and progesterone receptor) and human epidermal growth factor receptor 2 status in the primary tumor is clinically relevant to define breast cancer subtypes, clinical outcome, and the choice of therapy.
Carmen Criscitiello, Thompson, Alastair M., Locatelli, Marzia, Curigliano, Giuseppe, Orsi, Franco, F. Orsi, Fabrice André, Criscitiello, Carmen, Minchella, Ida, M. Locatelli, F. André, Thompson, Alastair M, Marzia Locatelli, Giuseppe Curigliano, Curigliano, Guiseppe, Ida Minchella, De Laurentiis, Michele, Lucia Gelao, Luca Fumagalli, Franco Orsi, Esposito, Angela, Goldhirsch, Aron, Angela Esposito, A. M. Thompson, DE LAURENTIIS, MICHELINO, L. Fumagalli, A. Goldhirsch, André, Fabrice, Michele De Laurentiis, Alastair M Thompson, A. Esposito, Fumagalli, Luca, G. Curigliano, M. De Laurentiis, Aron Goldhirsch, C. Criscitiello, L. Gelao, Gelao, Lucia, I. Minchella   +38 more
core   +1 more source

Re-evaluation of HER2 status in metastatic breast cancer and tumor-marker guided therapy with vinorelbine and trastuzumab [PDF]

, 2005
Background: HER2 is overexpressed in 20 - 30% of breast cancers. Compared to chemotherapy alone, chemotherapy with trastuzumab improves clinical outcome in patients with HER2- positive metastatic breast cancer ( MBC). In general, HER2 status in a primary
Lässig, D., Stemmler, H. J., Stieber, P., Heinemann, Volker   +3 more
core   +1 more source

Gemcitabine and carboplatin in intensively pretreated patients with metastatic breast cancer [PDF]

, 2007
Background: Patients with metastatic breast cancer (MBC) are increasingly exposed to anthracyclines and taxanes either during treatment of primary breast cancer or during initial therapy of metastatic disease.
Vehling-Kaiser, U., Melchert, F., Koelbl, H., Maubach, P., Stemmler, H. J., Scharl, A., Heinemann, Volker, Weber, B., Meerpohl, H., Kalischefski, B., Laessig, D., Stauch, M., Morack, G., Fasching, P. A.   +13 more
core   +1 more source

Role of gemcitabine in the treatment of advanced and metastatic breast cancer [PDF]

, 2003
Gemcitabine is an antimetabolite drug with proven antitumor activity and tolerability in metastatic breast cancer. In a total of nine studies, gemcitabine monotherapy has reached response rates of up to 37% in the first-line setting, 26% in the second ...
Heinemann, Volker
core   +1 more source

Lapatinib in Metastatic Breast Cancer [PDF]

Women's Health, 2009
Lapatinib is an oral, small-molecule, dual kinase inhibitor that targets both HER2 and the EGF receptor. Lapatinib was approved in June 2008 in Europe for the treatment of advanced HER2-positive breast cancer. Promising results in trastuzumab-refractory metastatic breast cancer were obtained from Phase I, II and III studies in combination with ...
J-S, Frenel, E, Bourbouloux, D, Berton-Rigaud, S, Sadot-Lebouvier, A, Zanetti, M, Campone   +5 more
openaire   +2 more sources

Moonshots and metastatic disease: the need for a multi-faceted approach when studying atypical responses

npj Breast Cancer, 2017
Clinical research generally focuses on results involving a statistical mean with little attention in trial design to patients who respond considerably better or worse than average.
Kristine De La Torre, Elly Cohen, Anne Loeser, Marc Hurlbert, on behalf of the Metastatic Breast Cancer Alliance   +4 more
doaj   +1 more source

Prognostic factors in metastatic breast cancer: a prospective single-centre cohort study in a Finnish University Hospital

BMJ Open, 2020
Objectives Although novel early breast cancer prognostic factors are being continuously discovered, only rare factors predicting survival in metastatic breast cancer have been validated.
Peeter Karihtala, Anniina Jääskeläinen, Nelli Roininen, Arja Jukkola   +3 more
doaj   +1 more source

In silico analysis of differentially expressed genesets in metastatic breast cancer identifies potential prognostic biomarkers

World Journal of Surgical Oncology, 2021
Background Identification of specific biological functions, pathways, and appropriate prognostic biomarkers is essential to accurately predict the clinical outcomes of and apply efficient treatment for breast cancer patients.
Jongchan Kim
doaj   +1 more source

The Metabolic Mechanisms of Breast Cancer Metastasis

Frontiers in Oncology, 2021
Breast cancer is one of the most common malignancy among women worldwide. Metastasis is mainly responsible for treatment failure and is the cause of most breast cancer deaths.
Lingling Wang, Lingling Wang, Shizhen Zhang, Xiaochen Wang   +3 more
doaj   +1 more source

High efficacy and low toxicity of weekly docetaxel given as first-line treatment for metastatic breast cancer [PDF]

, 2005
Background: Docetaxel is one of the most effective antitumor agents currently available for the treatment of metastatic breast cancer (MBC). This phase II multicenter study prospectively analyzed the efficacy and toxicity of docetaxel given on a weekly ...
Abenhardt, Wolfgang, Leinung, S., V. Heinemann, Stemmler, J., W. Mair, Jackisch, C., O. Brudler, G. Deutsch, Stamp, J., Dorn, B., J. Stemmler, Brudler, O., Stauch, M., M. Malekmohammadi, Papke, J., M. Stauch, Deutsch, G., Vehling-Kaiser, U., S. Leinung, B. Dorn, Heinemann, Volker, C. Jackisch, U. Vehling-Kaiser, Mair, W., Kentenich, C., J. Papke, C. Kentenich, Malekmohammadi, M., W. Abenhardt, J. Stamp   +29 more
core   +1 more source